| Literature DB >> 25881592 |
Xian-Bo Pei, Peng-Lin Ma, Jian-Guo Li1, Zhao-Hui Du, Qing Zhou, Zhang-Hong Lu, Luo Yun, Bo Hu.
Abstract
BACKGROUND: Inconsistencies in the use of the vasoactive agent therapy to treat shock are found in previous studies. A descriptive study was proposed to investigate current use of vasoactive agents for patients with shock in Chinese intensive care settings.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25881592 PMCID: PMC4832938 DOI: 10.4103/0366-6999.155064
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
First choice of vasopressor selected by respondents for management of septic, hypovolemic, and cardiogenic shock (n = 586) (n (%))
| Vasopressors | Septic | Hypovolemic | Cardiogenic | |
|---|---|---|---|---|
| Norepinephrine | 415 (70.8) | 133 (22.7)* | 111 (18.9)* | <0.01 |
| Dopamine | 162 (27.6) | 430 (73.4)* | 400 (68.3)* | <0.01 |
| Epinephrine | 5 (0.9) | 8 (1.4) | 38 (6.5)*,† | <0.01 |
| Others | 4 (0.7) | 15 (2.5)* | 37 (6.3)*,† | <0.01 |
*P<0.01 compared with septic shock; †P<0.01 compared with hypovolemic shock.
Percentage of respondents in selection of vasopressor as the first choice for shock management
| Items | Physicians from hospital ( | Staff ( | ||||
|---|---|---|---|---|---|---|
| T ( | NT ( | Senior ( | Junior ( | |||
| Vasopressors for septic shock | ||||||
| Norepinephrine | 294 (74.4) | 121 (63.4) | 0.006 | 180 (72.6) | 235 (69.5) | 0.422 |
| Dopamine | 96 (24.3) | 66 (34.6) | 0.009 | 63 (25.4) | 99 (29.3) | 0.299 |
| Epinephrine | 3 (0.8) | 2 (1.0) | 0.723 | 3 (1.2) | 2 (0.6) | 0.655 |
| Others | 2 (0.5) | 2 (1.0) | 0.600 | 2 (0.8) | 2 (0.6) | 1.000 |
| Vasopressors for hypovolemic shock | ||||||
| Norepinephrine | 105 (26.6) | 28 (14.7) | 0.001 | 57 (23.0) | 76 (22.5) | 0.887 |
| Dopamine | 276 (69.8) | 154 (80.6) | 0.006 | 178 (71.8) | 252 (74.5) | 0.452 |
| Epinephrine | 7 (1.8) | 1 (0.5) | 0.448 | 4 (1.6) | 4 (1.2) | 0.727 |
| Others | 7 (1.8) | 8 (4.2) | 0.097 | 9 (3.6) | 6 (1.8) | 0.160 |
| Vasopressors for cardiogenic shock | ||||||
| Norepinephrine | 93 (23.5) | 18 (9.4) | <0.01 | 43 (17.3) | 68 (20.1) | 0.396 |
| Dopamine | 253 (64.1) | 147 (77.0) | 0.002 | 172 (69.4) | 228 (67.5) | 0.626 |
| Epinephrine | 35 (8.9) | 3 (1.6) | 0.001 | 16 (6.5) | 22 (6.5) | 0.978 |
| Others | 14 (3.5) | 23 (12.0) | <0.01 | 17 (6.8) | 20 (5.9) | 0.520 |
T: Teaching hospital; NT: Nonteaching hospital.
First choice of inotrope selected by respondents for management of septic, hypovolemic, and cardiogenic shock (n (%))
| Items | Septic ( | Hypovolemic ( | Cardiogenic ( | |
|---|---|---|---|---|
| Dobutamine | 493 (84.1) | 207 (64.5)* | 355 (60.6)* | <0.01 |
| Digitalis | 70 (11.9) | 89 (27.7)* | 174 (29.7)* | <0.01 |
| Others | 23 (4.0) | 25 (7.8) | 57 (9.7)* | <0.01 |
*P<0.01 compared with septic shock. No significant difference was found between cardiogenic shock and hypovolemic shock.
Percentage of respondents in selection of inotrope as the first choice for shock management
| Items | Physicians from hospital | Staff | ||||
|---|---|---|---|---|---|---|
| T ( | NT ( | Senior ( | Junior ( | |||
| Inotropes for septic shock, | ||||||
| Dobutamine | 344 (87.1) | 149 (78.0) | 0.005 | 211 (85.1) | 282 (83.4) | 0.589 |
| Digitalis | 37 (9.4) | 33 (17.3) | 0.006 | 28 (11.3) | 42 (12.4) | 0.675 |
| Others | 14 (3.5) | 9 (4.7) | 0.496 | 9 (3.6) | 14 (4.2) | 0.752 |
| Do you use inotropes for the treatment of patients with hypovolemic shock? | ||||||
| Use | 205 (51.9) | 116 (60.7) | 0.044 | 135 (54.4) | 186 (55.0) | 0.886 |
| Inotropes for hypovolemic shock, % ( | ||||||
| Dobutamine | 70.4 (151/205) | 54.9 (56/116) | <0.01 | 64.4 (87/135) | 64.0 (119/186) | 0.932 |
| Digitalis | 22.1 (44/205) | 36.9 (45/116) | 0.001 | 25.2 (34/135) | 30.1 (56/186) | 0.332 |
| Others | 7.5 (10/205) | 8.2 (15/116) | <0.01 | 10.4 (14/135) | 5.9 (11/186) | 0.141 |
| Inotropes for cardiogenic shock, | ||||||
| Dobutamine | 258 (65.3) | 97 (50.8) | 0.001 | 152 (61.3) | 203 (60.1) | 0.763 |
| Digitalis | 98 (24.8) | 76 (39.8) | <0.01 | 64 (25.8) | 110 (32.5) | 0.078 |
| Others | 39 (9.9) | 18 (9.4) | 0.863 | 32 (12.9) | 25 (7.4) | 0.026 |
T: Teaching hospital; NT: Nonteaching hospital.
Choices of vasodilators by respondents
| Items | All ( | Physicians from hospital ( | Staff ( | ||||
|---|---|---|---|---|---|---|---|
| T ( | NT ( | Senior ( | Junior ( | ||||
| Use vasodilators for management of shock | |||||||
| Never | 77 (13.1) | 44 (11.1) | 33 (17.3) | 0.039 | 12 (4.8) | 65 (19.2) | <0.01 |
| Vasodilators for the following type of shock | |||||||
| Septic | 189 (32.3) | 123 (31.1) | 66 (34.6) | 0.407 | 84 (33.9) | 105 (31.1) | 0.473 |
| Hypovolemic | 38 (6.5) | 29 (7.3) | 9 (4.7) | 0.226 | 14 (5.6) | 24 (7.1) | 0.480 |
| Cardiogenic | 393 (67.1) | 267 (67.6) | 126 (66.0) | 0.695 | 23 (9.3) | 17 (5.0) | 0.650 |
| Choice of vasodilators | |||||||
| NG | 417 (71.2) | 290 (73.4) | 127 (66.5) | 0.072 | 194 (78.2) | 223 (66.0) | 0.001 |
| SNP | 267 (45.6) | 171 (43.3) | 96 (50.3) | 0.112 | 130 (52.4) | 137 (40.5) | 0.004 |
| Phentolamine | 193 (32.9) | 128 (32.4) | 65 (34.0) | 0.695 | 102 (41.1) | 91 (26.9) | <0.01 |
| Others | 138 (23.5) | 94 (23.8) | 44 (23.0) | 0.839 | 65 (26.2) | 73 (21.6) | 0.194 |
T: Teaching hospital; NT: Nonteaching hospital; NG: Nitroglycerine; SNP: Sodium nitroprusside.
Management during the use of vasoactive agents for shock management by respondents
| Items | All ( | Physicians from hospital | Staff | ||||
|---|---|---|---|---|---|---|---|
| T ( | NT ( | Senior ( | Junior ( | ||||
| Is MAP threshold the same for the initiation of vasopressors in different types of shock? % ( | |||||||
| Yes | 45.8 (264/577) | 42.2 (166/393) | 53.3 (98/184) | 0.013 | 43.6 (105/241) | 47.3 (159/336) | 0.372 |
| Is MAP targeting the same for the use of vasopressors in different types of shock? % ( | |||||||
| Yes | 43.0 (247/575) | 38.2 (150/393) | 53.3 (97/182) | 0.001 | 36.9 (94/241) | 47.3 (153/334) | 0.104 |
| MAP threshold in septic shock, mmHg, mean (SD) | 64.3 (7.5) | 64.9 (7.4) | 63.0 (7.8) | 0.005 | 64.6 (8.4) | 64.1 (6.9) | 0.431 |
| MAP target in septic shock, mmHg, mean (SD) | 71.0 (10.8) | 71.3 (10.7) | 70.6 (11.0) | 0.470 | 70.3 (10.8) | 71.6 (10.8) | 0.184 |
| The 4 leading indications for inotropic therapy, | |||||||
| Hypotension | 470 (80.2) | 319 (80.8) | 151 (79.1) | 0.628 | 197 (79.4) | 273 (80.8) | 0.689 |
| Low CO/CI | 389 (66.4) | 277 (70.1) | 112 (58.6) | 0.006 | 172 (69.4) | 217 (64.2) | 0.192 |
| Cold extremities | 217 (37.0) | 140 (35.4) | 77 (40.3) | 0.252 | 86 (34.7) | 131 (38.8) | 0.312 |
| Oliguria | 181 (30.9) | 106 (26.8) | 75 (39.3) | 0.002 | 83 (33.5) | 98 (29.0) | 0.247 |
| The leading 4 parameters used for the endpoints in inotropic therapy, | |||||||
| MAP | 508 (86.7) | 349 (88.4) | 159 (83.2) | 0.088 | 215 (86.7) | 293 (86.7) | 0.998 |
| UO | 345 (58.9) | 221 (55.9) | 124 (64.9) | 0.039 | 144 (58.1) | 201 (59.5) | 0.733 |
| CO/CI | 294 (50.2) | 206 (52.2) | 88 (46.1) | 0.168 | 136 (54.8) | 158 (46.7) | 0.053 |
| BLC | 239 (40.8) | 165 (41.8) | 74 (38.7) | 0.484 | 110 (44.4) | 129 (38.2) | 0.132 |
| Use low dose of dopamine, | |||||||
| Yes | 166 (28.3) | 98 (24.8) | 68 (35.6) | 0.007 | 64 (25.8) | 102 (30.2) | 0.246 |
T: Teaching hospital; NT: Nonteaching hospital; MAP: Mean arterial pressure; CO/CI: Cardiac output/cardiac index; UO: Urine output; BLC: Blood lactate concentration; SD: Standard deviation.
Monitoring protocols when using vasoactive agent therapy for shock management by respondents
| Items | All ( | Physicians from hospital ( | Staff ( | ||||
|---|---|---|---|---|---|---|---|
| T ( | NT ( | Senior ( | Junior ( | ||||
| Routinely used monitoring devices/parameters | |||||||
| ECG | 586 (100.0) | 395 (100.0) | 191 (100.0) | 1.000 | 248 (100.0) | 338 (100.0) | 1.000 |
| NBP | 586 (100.0) | 395 (100) | 191 (100.0) | 1.000 | 248 (100.0) | 338 (100.0) | 1.000 |
| SpO2 | 586 (100.0) | 395 (100) | 191 (100.0) | 1.000 | 248 (100.0) | 338 (100.0) | 1.000 |
| Temperature | 586 (100.0) | 395 (100) | 191 (100.0) | 1.000 | 248 (100.0) | 338 (100.0) | 1.000 |
| Blood gas analysis | 577 (98.5) | 391 (99.0) | 186 (97.4) | 0.160 | 244 (98.4) | 333 (98.5) | 1.000 |
| CVP | 515 (87.9) | 348 (88.1) | 167 (87.4) | 0.817 | 224 (90.3) | 291 (86.1) | 0.121 |
| BLC | 496 (84.6) | 354 (89.6) | 142 (74.3) | <0.01 | 212 (85.5) | 284 (84.0) | 0.628 |
| IBP | 259 (44.2) | 186 (47.1) | 73 (38.2) | 0.043 | 109 (44.0) | 150 (44.4) | 0.918 |
| Often used advanced monitoring devices/parameters | |||||||
| PICCO | 134 (22.9) | 106 (26.8) | 28 (14.7) | <0.01 | 51 (20.6) | 83 (24.6) | 0.256 |
| PAC | 21 (3.6) | 19 (4.8) | 2 (1.0) | 0.022 | 10 (4.0) | 11 (3.3) | 0.617 |
| TEE | 2 (0.3) | 2 (0.5) | 0 (0) | 1.000 | 2 (0.8) | 0 (0) | 0.179 |
| GMMM | 3 (0.5) | 3 (0.8) | 0 (0) | 0.555 | 3 (1.2) | 0 (0) | 0.075 |
| SMM | 3 (0.5) | 3 (0.8) | 0 (0) | 0.555 | 3 (1.2) | 0 (0) | 0.075 |
T: Teaching hospital; NT: Nonteaching hospital; ECG: Electrocardiograph; NBP: Noninvasive blood pressure; SpO2: Pulse oximetry; IBP: Invasive blood pressure; CVP: Central venous pressure; PICCO: Pulse index contour continuous cardiac output; PAC: Pulmonary artery catheter; TEE: Transesophageal echocardiography; GMMM: Gastric mucosal microcirculatory monitoring; SMM: Sublingual microcirculatory monitoring; BLC: Blood lactate concentration.